{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:05:41Z","timestamp":1792807541336,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10147-021-01912-0","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T20:02:44Z","timestamp":1617220964000},"page":"1293-1303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy"],"prefix":"10.1007","volume":"26","author":[{"given":"Tsuyoshi","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7109-9835","authenticated-orcid":false,"given":"Takashi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisaki","family":"Suzumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Mie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"1","key":"1912_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1912_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17(6):801\u2013810","journal-title":"Lancet Oncol"},{"issue":"19","key":"1912_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825","journal-title":"N Engl J Med"},{"issue":"18","key":"1912_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703","journal-title":"N Engl J Med"},{"issue":"1","key":"1912_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pan.2019.11.012","volume":"20","author":"X Li","year":"2020","unstructured":"Li X, Huang DB, Zhang Q et al (2020) The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Pancreatology 20(1):95\u2013100","journal-title":"Pancreatology"},{"issue":"3","key":"1912_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.pan.2020.01.005","volume":"20","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Rogers JE, Hess KR et al (2020) Modified FOLFIRINOX in pancreatic cancer patients age 75 or older. Pancreatology 20(3):501\u2013504","journal-title":"Pancreatology"},{"issue":"2","key":"1912_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MPA.0000000000001484","volume":"49","author":"S Kobayashi","year":"2020","unstructured":"Kobayashi S, Ueno M, Ikeda M et al (2020) A multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer. Pancreas 49(2):187\u2013192","journal-title":"Pancreas"},{"issue":"5","key":"1912_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489\u2013495","journal-title":"Lancet Oncol"},{"issue":"1","key":"1912_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16\u201331","journal-title":"Age Ageing"},{"issue":"12","key":"1912_CR10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31(12):1539\u20131547","journal-title":"J Clin Oncol"},{"issue":"2","key":"1912_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcsm.12391","volume":"10","author":"IMG da Rocha","year":"2019","unstructured":"da Rocha IMG, Marcadenti A, de Medeiros GOC et al (2019) Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study. J Cachexia Sarcopenia Muscle 10(2):445\u2013454","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"9","key":"1912_CR12","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","volume":"28","author":"F Bozzetti","year":"2017","unstructured":"Bozzetti F (2017) Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol 28(9):2107\u20132118","journal-title":"Ann Oncol"},{"issue":"7","key":"1912_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4251\/wjgo.v11.i7.527","volume":"11","author":"MY Chan","year":"2019","unstructured":"Chan MY, Chok KSH (2019) Sarcopenia in pancreatic cancer\u2013effects on surgical outcomes and chemotherapy. World J Gastrointest Oncol 11(7):527\u2013537","journal-title":"World J Gastrointest Oncol"},{"issue":"5","key":"1912_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"issue":"2","key":"1912_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/MPA.0000000000000446","volume":"45","author":"H Imaoka","year":"2016","unstructured":"Imaoka H, Mizuno N, Hara K et al (2016) Evaluation of modified glasgow prognostic score for pancreatic cancer: a retrospective cohort study. Pancreas 45(2):211\u2013217","journal-title":"Pancreas"},{"key":"1912_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cca.2018.01.024","volume":"479","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Wei Q, Fan J et al (2018) Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients. Clin Chim Acta 479:181\u2013189","journal-title":"Clin Chim Acta"},{"issue":"9","key":"1912_CR17","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G (1984) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85(9):1001\u20131005","journal-title":"Nihon Geka Gakkai Zasshi"},{"issue":"3","key":"1912_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48(3):452\u2013458","journal-title":"Bone Marrow Transpl"},{"issue":"22","key":"1912_CR19","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR et al (2018) Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 36(22):2326\u20132347","journal-title":"J Clin Oncol"},{"issue":"24","key":"1912_CR20","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M et al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595\u20132603","journal-title":"J Clin Oncol"},{"issue":"1","key":"1912_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1146\/annurev-cancerbio-030419-033642","volume":"4","author":"AK Biswas","year":"2020","unstructured":"Biswas AK, Acharyya S (2020) Cancer-associated cachexia: a systemic consequence of cancer progression. Annu Rev Cancer Biol 4(1):391\u2013411","journal-title":"Annu Rev Cancer Biol"},{"issue":"8","key":"1912_CR22","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ejca.2008.02.033","volume":"44","author":"KC Fearon","year":"2008","unstructured":"Fearon KC (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44(8):1124\u20131132","journal-title":"Eur J Cancer"},{"issue":"Suppl 7","key":"1912_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00508-016-1087-5","volume":"128","author":"JE Morley","year":"2016","unstructured":"Morley JE (2016) Frailty and sarcopenia in elderly. Wien Klin Wochenschr 128(Suppl 7):439\u2013445","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"1912_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1139\/apnm-2013-0554","volume":"39","author":"FS Lira","year":"2014","unstructured":"Lira FS, Neto JC, Seelaender M (2014) Exercise training as treatment in cancer cachexia. Appl Physiol Nutr Metab 39(6):679\u2013686","journal-title":"Appl Physiol Nutr Metab"},{"issue":"12","key":"1912_CR25","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3390\/cancers11121861","volume":"11","author":"RF Dunne","year":"2019","unstructured":"Dunne RF, Loh KP, Williams GR et al (2019) Cachexia and sarcopenia in older adults with cancer: a comprehensive review. Cancers 11(12):1861","journal-title":"Cancers"},{"issue":"1","key":"1912_CR26","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s12885-019-5762-6","volume":"19","author":"S Miura","year":"2019","unstructured":"Miura S, Naito T, Mitsunaga S et al (2019) A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. BMC Cancer 19(1):528","journal-title":"BMC Cancer"},{"issue":"4","key":"1912_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC et al (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17(4):519\u2013531","journal-title":"Lancet Oncol"},{"issue":"3","key":"1912_CR28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T et al (2018) Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124(3):606\u2013616","journal-title":"Cancer"},{"issue":"23","key":"1912_CR29","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","volume":"125","author":"S Hamauchi","year":"2019","unstructured":"Hamauchi S, Furuse J, Takano T et al (2019) A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125(23):4294\u20134302","journal-title":"Cancer"},{"issue":"9","key":"1912_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1177\/2050640620938987","volume":"8","author":"D Iglesia","year":"2020","unstructured":"Iglesia D, Avci B, Kiriukova M et al (2020) Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis. United Eur Gastroenterol J 8(9):1115\u20131125","journal-title":"United Eur Gastroenterol J"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01912-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-01912-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01912-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T04:08:16Z","timestamp":1624075696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-01912-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1912"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-01912-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interests for this article. Conflicts of interests outside this work are as follows; Naoki Sasahira received research funding from Zeria, Eisai, Kyowa Hakko Kirin, Baxalta and Taiho Pharmaceutical. Masato Ozaka received honoraria from Taiho Pharmaceutical, Yakult, Bayer, Pfizer, Novartis, Takeda Pharmaceutical Company Limited, Eisai, EA pharma and Mitsubishi Tanabe Pharma Corporation and research funding from Merck & Co., Inc., Incyte, ASLAN Pharmaceuticals, Taiho Pharmaceutical and Yakult. Takashi Sasaki received honoraria from Taiho Pharmaceutical and Eisai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of our institution (Institutional Review Board number: 2020-1210).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}